Women's Sex Drive Pill Is Defended by FDA, With Caveats

  • Addyi approved in August, sold by Valeant Pharmaceuticals
  • Agency officials say women should be able to decide on drug

The Road Ahead for Addyi: Why Did Sprout's CEO Leave?

Approving a pill to boost women’s sex drive was the right decision and patients should be able to make their own call about taking it, the U.S. Food and Drug Administration said in an essay defending the agency’s move in a leading medical journal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.